8441B707-EC45-4A38-8B83-99B8D83CCF8B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 29.829172141918527
- age_years
- 48
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.502
- NOTCH_SIGNALING+0.440
- WNT_BETA_CATENIN_SIGNALING+0.387
- PROTEIN_SECRETION+0.341
- TGF_BETA_SIGNALING+0.320
- MITOTIC_SPINDLE+0.317
- ANDROGEN_RESPONSE+0.309
- UNFOLDED_PROTEIN_RESPONSE+0.309
- MTORC1_SIGNALING+0.270
- MYC_TARGETS_V1+0.250
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.333
- KRAS_SIGNALING_DN-0.329
- SPERMATOGENESIS-0.272
- COAGULATION-0.242
- PANCREAS_BETA_CELLS-0.210
- ANGIOGENESIS-0.195
- ALLOGRAFT_REJECTION-0.175
- APICAL_SURFACE-0.132
- MYOGENESIS-0.105
- COMPLEMENT-0.074
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.916 |
| 2 | 6114E89B-B007-4F1B-B086-21ADE26F4573 | — | — | 0.907 |
| 3 | 37A8E941-F86F-449A-86E4-833AC349111F | — | — | 0.892 |
| 4 | SRR934756 | — | — | 0.886 |
| 5 | SRR934799 | — | — | 0.884 |
| 6 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.883 |
| 7 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.882 |
| 8 | SRR934725 | — | — | 0.874 |
| 9 | C6ACBA34-164B-419D-9C2B-ED2DC3C68FDD | — | — | 0.873 |
| 10 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.502 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.440 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.387 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.341 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.317 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.309 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.309 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.249 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.249 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.234 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.206 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.205 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.198 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.198 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.188 | Inavolisib | — uncovered |
| PEROXISOME | 0.181 | Idelalisib | — uncovered |